HIV-2 Resistance Interpretation and Case Report PD Dr. Martin - - PowerPoint PPT Presentation
HIV-2 Resistance Interpretation and Case Report PD Dr. Martin - - PowerPoint PPT Presentation
HIV-2 Resistance Interpretation and Case Report PD Dr. Martin Strmer Institute for Medical Virology University Clinic Frankfurt/Main HIV-2 Wildtype What happens, if you submit the HIV-2 wildtype sequence ROD to online-tools for
HIV-2 Wildtype
What happens, if you submit the HIV-2
wildtype sequence ROD to online-tools for interpretation of HIV drug resistance?
HIV-2 Wildtype
HIV-2 Wildtype
HIV-2 Wildtype
And where is the Protease???
HIV-2 Wildtype
HIV-2 Wildtype
HIV-2 Resistence Interpretation
NRTIs
– no concordance between algorithms – 3TC, FTC, ABC, TDF < ddI < AZT, d4T
NNRTIs
– Forget it
PIs
– some concordance between algorithms – SQV < DRV, LPV < NFV < IDV, ATV < FPV, TPV
INIs
– Yes
HIV-2 Resistence Interpretation
Current approach
– PR: enter all AA differences from consensus HIV-1 manually into the algorithm – RT: submit the complete sequence to the algorithm – IN: submit the complete sequence to the algorithm
Is this correct?
– What do we know about interactions between mutations in HIV-2???
Case Report
Male Portuguese patient Risk unknown First positive HIV test 01/1991 First visit in FFM 09/2000 with 55 CD4 (13,8%)
and 41.400 copies/ml
Therapy start 02/2003
1 10 100 1.000 10.000 100.000 Sep. 00 May. 03 Dez. 03 Dez. 04 Sep. 05 Feb. 07 Jul. 07 Jan. 08 Sep. 08 Apr. 09 H I V R N A [ K
- p
i e n / m l ] 200 400 600 800 C D 4 [ Z e l l e n / µ l ]
< 100
AZT AZT 3TC 3TC TDF TDF FTC FTC LPV/r LPV/r
Case Report
Adverse Event: high blood fat values
1 10 100 1.000 10.000 100.000 Sep. 00 May. 03 Dez. 03 Dez. 04 Sep. 05 Feb. 07 Jul. 07 Jan. 08 Sep. 08 Apr. 09 H I V R N A [ K
- p
i e n / m l ] 200 400 600 800 C D 4 [ Z e l l e n / µ l ]
< 100
AZT AZT 3TC 3TC TDF TDF FTC FTC LPV/r LPV/r
Case Report
Resistance Test
Discussion
1 10 100 1.000 10.000 100.000 Sep. 00 May. 03 Dez. 03 Dez. 04 Sep. 05 Feb. 07 Jul. 07 Jan. 08 Sep. 08 Apr. 09 H I V R N A [ K
- p
i e n / m l ] 200 400 600 800 C D 4 [ Z e l l e n / µ l ]
< 100
AZT AZT 3TC 3TC TDF TDF FTC FTC LPV/r LPV/r DRV/r DRV/r SQV/r SQV/r RAL RAL